The Liechtenstein Institute on Self-Determination will host a  "Global Health Impact" workshop on Friday, May 10, 2019, from 12:00-5:00 p.m. in 002 Robertson Hall (full schedule here), focusing on the initiative spearheaded by the Global Health Impact Organization to evaluate and compare medicines' global health impact. The Global Health Impact Organization is a collaboration of researchers from universities and civil society organizations from around the world, dedicated to measuring pharmaceutical products’ impact on global health to advance access to essential medicines. The workshop is co-sponsored by the Global Health Program, the Program in African Studies, and the Program in Law and Public Affairs. To attend, RSVP to Angella Sandford.

The Global Health Impact index was first launched at the World Health Organization in Geneva in 2015. At the Princeton relaunch event, its new website and models will be introduced and two roundtable discussions will follow, linking the project to the Sustainable Development Goals.

The Sustainable Development Goals aim to, “by 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases,” and ensure “access to safe, effective, quality and affordable essential medicines and vaccines for all” (SDG3). According to recent World Health Organization research, access to medicines and vaccinations in developing countries (SDG3b) remains low – global vaccination coverage stands at 85%, antiretroviral therapy only reaches half of those living with HIV, and progress to end malaria has stalled. Many countries in the Global South furthermore still lack the capacity for early warning, risk reduction, and management of national and global health risks (SDG3d).

The Global Health Impact (GHI) project seeks to constructively intervene in the policy debates around global health. The GHI project is a collaboration of researchers from civil society organizations and universities from around the world, committed to alleviating the global burden of disease. Under the direction of Prof. Nicole Hassoun (Binghamton University and Cornell University), they produce some of the most comprehensive models of essential medicines’ health consequences around the world to better advance access to treatment. The GHI index aims to measure the consequences of pharmaceutical products on global health, and estimates the disease impact in the absence of treatment using data on drug efficacy, disease incidence, and the global burden of disease remaining post-treatment. Ultimately, by illustrating this impact, the index can incentivize pharmaceutical companies and policy-makers to extend access to treatments in endemic regions.

Participants include:

Jason F. Arnold, Senior Fellow and Assistant Director, Clinical and Translational Research Ethics, Institute of Human Values in Health Care, Medical University of South Carolina 
Walden Bello, Former Member of the House of Representatives, Philippines, and Executive Director of Focus on the Global South  
Barbara Buckinx, Associate Research Scholar, Liechtenstein Institute on Self-Determination, Woodrow Wilson School of Public and International Affairs, Princeton University 
Marc Fleurbaey, Robert E. Kuenne Professor in Economics and Humanistic Studies, Professor of Public Affairs and the University Center for Human Values, Princeton University 
Sean Flynn, Program on Information Justice and Intellectual Property, Washington Law School, American University  
Sakiko Fukuda-Parr, UN High-Level Panel on Access to Medicines, Professor of International Affairs at the New School, former Director and lead author of the UNDP Human Development Reports (1995-2004)  
Alexandra Greenberg, Global Executive Committee, Universities Allied for Essential Medicines 
Nicole Hassoun, Founder of the Global Health Impact project, Professor of Philosophy, Binghamton University, and Visiting Scholar, Cornell University  
Susan Hayes, Global Head, Corporate Responsibility, Novartis 
Aidan Hollis, President and Director, Incentives for Global Health, Professor of Economics, University of Calgary 
Suraj Madoori, US and Global Health Policy Director, Treatment Action Group 
Jennifer Miller, Founder of the Good Pharma Scorecard, Assistant Professor, School of Medicine, Yale University   
Sherif Mowafy, Branch Chief, Supply Chain for Health Division, Office of HIV/AIDS, USAID
Jerry Nutor, Postdoctoral Research Associate, Center for Health and Wellbeing, Woodrow Wilson School for Public and International Affairs, Princeton University 
Olugbenga Ogedegbe, Professor of Population Health and Medicine, Chief of the Division of Health and Behavior, and Director of the Center for Healthful Behavior Change in the Department of Population Health, New York University Langone